Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Share:
Related MDT
Medtronic Study Detects Gene Associated with Sudden Cardiac Death
High Expectations For Ambarella In An Otherwise Quiet Earnings Week
Medtronic buys brain aneurysm treatment device maker for $150M+ (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Latest Ratings for MDT

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Jul 2015BTIG ResearchUpgradesNeutralBuy
Mar 2015BMO CapitalMaintainsOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MDT)

Get Benzinga's Newsletters